ClinicalTrials.Veeva

Find clinical trials for COVID-19 in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Communicable Diseases
Coronavirus Infections
Pneumonia
Post-Acute COVID-19 Syndrome
Syndrome
Human Influenza

COVID-19 trials near Barcelona, CT, ESP:

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infe...

Active, not recruiting
COVID-19
Biological: Placebo
Biological: Remdesivir

Phase 3

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)

Barcelona, Spain and 123 other locations

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and fun...

Active, not recruiting
Post-COVID-19 Syndrome
Drug: Placebo
Drug: Temelimab 54mg/kg

Phase 2

GeNeuro

Barcelona, Spain and 13 other locations

Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia (TRICOVID)

pneumonia (CAP) or moderate / severe Coronavirus Disease 2019 (COVID-19) pneumonia.Other objectives are to determine pharmacokineti...

Enrolling
COVID-19
Bacterial Pneumonia
Drug: Placebo (human albumin 1%)
Drug: Trimodulin

Phase 3

Biotest

Barcelona, Spain and 58 other locations

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.The aim of the Phase I/III study (Parent Study) will -...

Active, not recruiting
COVID-19, SARS-CoV-2
Biological: AZD3152 (Parent study Main Cohort)
Biological: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152

Phase 2, Phase 3

AstraZeneca
AstraZeneca

Barcelona, Spain and 214 other locations

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need t...

Active, not recruiting
COVID-19
SARS CoV 2 Infection
Drug: Bemnifosbuvir (BEM)
Drug: Placebo

Phase 3

Atea Pharmaceuticals
Atea Pharmaceuticals

Barcelona, Spain and 263 other locations

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), ...

Enrolling
Respiratory Syncytial Virus Infections
Biological: COVID-19 mRNA vaccine
Biological: RSVPreF3 OA investigational vaccine

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Barcelona, Spain and 24 other locations

Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as...

Enrolling
SARS CoV 2 Infection
Biological: BIMERVAX

Phase 2

Hipra

Barcelona, Spain and 6 other locations

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tol...

Active, not recruiting
SARS-CoV2 Infection
Biological: PHH-1V81
Biological: Comirnaty Omicron XBB1.5

Phase 2, Phase 3

Hipra

Barcelona, Spain and 9 other locations

EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.

Enrolling
SARS-CoV-2
Drug: Placebo
Drug: Eicosapentaenoic acid gastro-resistant capsules

Phase 3

S.L.A. Pharma

Barcelona, Spain and 4 other locations

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants...

Enrolling
Sickle Cell Disease (SCD)
Drug: Crizanlizumab

Phase 2

Novartis
Novartis

Barcelona, Catalunya, Spain and 56 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems